HOUSTON, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2016 American Society of Hematology (ASH) Annual Meeting, taking place from December 3-6, 2016 in San Diego, CA.
Dr. Ana Tari Ashizawa, Director of Research at Bio-Path, will present preclinical and clinical data of BP1001 (Liposomal Grb2 antisense) for the treatment of chronic myeloid leukemia (CML).
Details for the poster presentation are as follows:
Date: Monday, December 5, 2016
Presentation Time: 6:00 pm – 8:00 pm Pacific Time
Location: San Diego Convention Center, Hall GH
Session: Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy
Title: “BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia” (Link to abstract)
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Last updated on: 07/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.